Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Juan Pablo Frías. (2023) An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program. Expert Review of Endocrinology & Metabolism 18:2, pages 111-130.
Read now
Read now
Lina Naseralallah & Bodoor Aboujabal. (2023) Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy. Expert Opinion on Pharmacotherapy 24:4, pages 407-418.
Read now
Read now
Bin Yang, Ana Gomes Dos Santos, Sanyogitta Puri, Annette Bak & Liping Zhou. (2022) The industrial design, translation, and development strategies for long-acting peptide delivery. Expert Opinion on Drug Delivery 19:10, pages 1233-1245.
Read now
Read now
Articles from other publishers (30)
Nour Zaïmia, Joelle Obeid, Annie Varrault, Julia Sabatier, Christophe Broca, Patrick Gilon, Safia Costes, Gyslaine Bertrand & Magalie A. Ravier. (2023) GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function. Cell Reports 42:11, pages 113326.
Crossref
Crossref
Chiara Ruocco, Alexis Elias Malavazos, Maurizio Ragni, Michele O. Carruba, Alessandra Valerio, Gianluca Iacobellis & Enzo Nisoli. (2023) Amino acids contribute to adaptive thermogenesis. New insights into the mechanisms of action of recent drugs for metabolic disorders are emerging. Pharmacological Research 195, pages 106892.
Crossref
Crossref
Ana Luiza Arruda, April Hartley, Georgia Katsoula, George Davey Smith, Andrew P. Morris & Eleftheria Zeggini. (2023) Genetic underpinning of the comorbidity between type 2 diabetes and osteoarthritis. The American Journal of Human Genetics 110:8, pages 1304-1318.
Crossref
Crossref
Dimitrios Patoulias, Athina Dimosiari & Nikolaos Fragakis. (2023) Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?. Future Cardiology.
Crossref
Crossref
Tito Borner, Benjamin C. Reiner, Richard C. Crist, C. Daniel Furst, Sarah A. Doebley, Julia G. Halas, Minrong Ai, Ricardo J. Samms, Bart C. De Jonghe & Matthew R. Hayes. (2023) GIP receptor agonism blocks chemotherapy-induced nausea and vomiting. Molecular Metabolism 73, pages 101743.
Crossref
Crossref
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang & Jincheng Wang. (2023) Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 13:6, pages 2383-2402.
Crossref
Crossref
Mariana Abdel-Malek, Lisa Yang & Alexander Dimitri Miras. (2023) Pharmacotherapy for chronic obesity management: a look into the future. Internal and Emergency Medicine 18:4, pages 1019-1030.
Crossref
Crossref
Fei Lin, Bin Yu, Baodong Ling, Guangyao Lv, Huijun Shang, Xia Zhao, Xiaoling Jie, Jing Chen & Yan Li. (2023) Weight loss efficiency and safety of tirzepatide: A Systematic review. PLOS ONE 18:5, pages e0285197.
Crossref
Crossref
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant & Melanie J. Davies. (2023) Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Journal of Obesity & Metabolic Syndrome 32:1, pages 25-45.
Crossref
Crossref
Mads M Helsted, Lærke S Gasbjerg, Tina Vilsbøll, Casper K Nielsen, Julie L Forman, Mikkel B Christensen & Filip K Knop. (2023) Separate and combined effects of long-term GIP and GLP-1 receptor
activation in patients with type 2 diabetes: a structured summary of a study
protocol for a double-blind, randomised, placebo-controlled clinical
trial. BMJ Open 13:2, pages e065736.
Crossref
Crossref
Giovanni Targher, Alessandro Mantovani & Christopher D Byrne. (2023) Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. The Lancet Gastroenterology & Hepatology 8:2, pages 179-191.
Crossref
Crossref
Caroline E. Geisler, Meghan P. Antonellis, Wolfgang Trumbauer, Jennifer A. Martin, Tamer Coskun, Ricardo J. Samms & Matthew R. Hayes. (2022) Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes, Obesity and Metabolism 25:1, pages 56-67.
Crossref
Crossref
Amrit Bhusal. (2023) Advent of tirzepatide: boon for diabetic and obese?. Annals of Medicine & Surgery 85:2, pages 71-72.
Crossref
Crossref
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, Stanislovas S. Jankauskas, Pasquale Mone & Gaetano Santulli. (2022) Tirzepatide: A Systematic Update. International Journal of Molecular Sciences 23:23, pages 14631.
Crossref
Crossref
Liliane El Eid, Christopher A. Reynolds, Alejandra Tomas & Ben Jones. (2022) Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics. Pharmacological Research 184, pages 106411.
Crossref
Crossref
Ricardo J. Samms, GuoFang Zhang, Wentao He, Olga Ilkayeva, Brian A. Droz, Steven M. Bauer, Cynthia Stutsman, Valentina Pirro, Kyla A. Collins, Ellen C. Furber, Tamer Coskun, Kyle W. Sloop, Joseph T. Brozinick & Christopher B. Newgard. (2022) Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Molecular Metabolism 64, pages 101550.
Crossref
Crossref
Rouchan Ali, Sharma Arvind Virendra & Pooja A Chawla. (2022) Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist. Health Sciences Review 4, pages 100032.
Crossref
Crossref
Tamer Coskun, Shweta Urva, William C. Roell, Hongchang Qu, Corina Loghin, Julie S. Moyers, Libbey S. O’Farrell, Daniel A. Briere, Kyle W. Sloop, Melissa K. Thomas, Valentina Pirro, David B. Wainscott, Francis S. Willard, Matthew Abernathy, LaRonda Morford, Yu Du, Charles Benson, Ruth E. Gimeno, Axel Haupt & Zvonko Milicevic. (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism 34:9, pages 1234-1247.e9.
Crossref
Crossref
Vivek P. Chavda, Jinal Ajabiya, Divya Teli, Joanna Bojarska & Vasso Apostolopoulos. (2022) Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules 27:13, pages 4315.
Crossref
Crossref
Natasha P Malkani & Vanita R Aroda. (2022) SURPASSing the current dogma: is our framework shifting?. The Lancet Diabetes & Endocrinology 10:6, pages 375-376.
Crossref
Crossref
Bingfa Sun, Francis S. Willard, Dan Feng, Jorge Alsina-Fernandez, Qi Chen, Michal Vieth, Joseph D. Ho, Aaron D. Showalter, Cynthia Stutsman, Liyun Ding, Todd M. Suter, James D. Dunbar, John W. Carpenter, Faiz Ahmad Mohammed, Eitaro Aihara, Robert A. Brown, Ana B. Bueno, Paul J. Emmerson, Julie S. Moyers, Tong Sun Kobilka, Matthew P. Coghlan, Brian K. Kobilka & Kyle W. Sloop. (2022) Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences 119:13.
Crossref
Crossref
Fei-Fei Xie, Yu-Fang Zhang, Yan-Fang Hu, Yun-Yun Xie, Xiao-Ying Wang, Shu-Zhen Wang & Bao-Qiang Xie. (2022) Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis. World Journal of Clinical Cases 10:5, pages 1527-1535.
Crossref
Crossref
Tito Borner, Ian C. Tinsley, Robert P. Doyle, Matthew R. Hayes & Bart C. De Jonghe. (2021) Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. British Journal of Pharmacology 179:4, pages 542-556.
Crossref
Crossref
Neil Tanday, Peter R. Flatt & Nigel Irwin. (2021) Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands. British Journal of Pharmacology 179:4, pages 526-541.
Crossref
Crossref
Renata Spezani & Carlos Alberto Mandarim-de-Lacerda. (2022) The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon. Life Sciences 288, pages 120188.
Crossref
Crossref
Akshaya Srikanth Bhagavathula, Kota Vidyasagar & Wubshet Tesfaye. (2021) Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials. Pharmaceuticals 14:10, pages 991.
Crossref
Crossref
Safia Costes, Gyslaine Bertrand & Magalie A. Ravier. (2021) Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies. International Journal of Molecular Sciences 22:10, pages 5303.
Crossref
Crossref
Mohamed Suliman & NagiHashim Mohammed. (2021)
Conference highlights: The 81
st
Annual (Virtual) conference of the American diabetes association: June 25–29, 2021
. Journal of Diabetes and Endocrine Practice 4:3, pages 143.
Crossref
Crossref
Najeeb Shah, Mohammed Altigani Abdalla, Harshal Deshmukh & Thozhukat Sathyapalan. (2021) Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882110421.
Crossref
Crossref
K. Clément & O. Ziegler. 2021. Les Obésités. Les Obésités
663
672
.